Role of nucleophosmin in acute myeloid leukemia

被引：29
作者：
Meani, Natalia [1 ]
Alcalay, Myriam [1 ,2 ]
机构：
[1] Ist Europeo Oncol, I-20139 Milan, Italy
[2] Univ Milan, Dipartimento Med Chirurg & Odontoiatria, Milan, Italy
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2009年 / 9卷 / 09期
关键词：
acute myeloid leukemia; chromosomal translocations; normal karyotype; NPM mutations; nucleophosmin; protein-protein interactions; subcellular localization; ACUTE MYELOGENOUS LEUKEMIA; MINIMAL RESIDUAL DISEASE; ARF TUMOR-SUPPRESSOR; ACUTE PROMYELOCYTIC LEUKEMIA; GENE-EXPRESSION PROFILE; NF-KAPPA-B; NUCLEOLAR PROTEIN B23/NUCLEOPHOSMIN; SUMO-SPECIFIC PROTEASE; TRANS-RETINOIC ACID; VIRUS CORE PROTEIN;
D O I：
10.1586/ERA.09.84
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Nucleophosmin (NPM) is a nucleolar phosphoprotein implicated in the regulation of multiple cellular functions, which possesses both oncogenic and tumor-suppressor properties. Mutations of the NPM1 gene leading to the expression of a cytoplasmic mutant protein, NPMc+, are the most frequent genetic abnormalities found in acute myeloid leukemias. Acute myeloid leukemias with mutated NPM1 have distinct characteristics, including a significant association with a normal karyotype, involvement of different hematopoietic lineages, a specific gene-expression profile and clinically, a better response to induction therapy and a favorable prognosis. NPMc+ maintains the capacity of wild-type NPM to interact with a variety of cellular proteins, and impairs their activity by delocalizing them to the cytoplasm. In this review we summarize recent discoveries concerning NPM function, and discuss their possible impact on the pathogenesis of acute myeloid leukemias with mutated NPM1.
引用
收藏
页码：1283 / 1294
页数：12
相关论文
共 154 条
[1]  
ADACHI Y, 1993, J BIOL CHEM, V268, P13930
[2]   Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance [J].
Alcalay, M ;
Tiacci, E ;
Bergomas, R ;
Bigerna, B ;
Venturini, E ;
Minardi, SP ;
Meani, N ;
Diverio, D ;
Bernard, L ;
Tizzoni, L ;
Volorio, S ;
Luzi, L ;
Colombo, E ;
Lo Coco, F ;
Mecucci, C ;
Falini, B ;
Pelicci, PG .
BLOOD, 2005, 106 (03) :899-902
[3]   Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC [J].
Ammatuna, E ;
Noguera, NI ;
Zangrilli, D ;
Curzi, P ;
Panetta, P ;
Bencivenga, P ;
Amadori, S ;
Federici, G ;
Lo-Coco, F .
CLINICAL CHEMISTRY, 2005, 51 (11) :2165-2167
[4]   NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features [J].
Andersen, M. T. ;
Andersen, M. K. ;
Christiansen, D. H. ;
Pedersen-Bjergaard, J. .
LEUKEMIA, 2008, 22 (05) :951-955
[5]  
[Anonymous], MITELMAN DATABASE CH
[6]   The κ promoter penta-decamer binding protein CBF-A interacts specifically with nucleophosmin in the nucleus only [J].
Aranburu, A ;
Bennett, M ;
Leanderson, T .
MOLECULAR IMMUNOLOGY, 2006, 43 (06) :690-701
[7]   MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia [J].
Armstrong, SA ;
Staunton, JE ;
Silverman, LB ;
Pieters, R ;
de Boer, ML ;
Minden, MD ;
Sallan, SE ;
Lander, ES ;
Golub, TR ;
Korsmeyer, SJ .
NATURE GENETICS, 2002, 30 (01) :41-47
[8]   Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation [J].
Bacher, Ulrike ;
Badbaran, Anita ;
Fehse, Boris ;
Zabelina, Tatjana ;
Zander, Axel Rolf ;
Kroeger, Nicolaus .
EXPERIMENTAL HEMATOLOGY, 2009, 37 (01) :135-142
[9]   Loss of the NPM1 gene in myeloid disorders with chromosome 5 rearrangements [J].
Berger, R ;
Busson, M ;
Baranger, L ;
Hélias, C ;
Lessard, M ;
Dastugue, N ;
Speleman, F .
LEUKEMIA, 2006, 20 (02) :319-321
[10]  
Bernard K, 2003, CANCER RES, V63, P6716
12345678910